Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Acute therapies continue to report strong growth compared to chronic ones.
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Subscribe To Our Newsletter & Stay Updated
